Catherine Thiéblemont

35.7k total citations · 4 hit papers
420 papers, 14.3k citations indexed

About

Catherine Thiéblemont is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Catherine Thiéblemont has authored 420 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 302 papers in Pathology and Forensic Medicine, 241 papers in Oncology and 155 papers in Genetics. Recurrent topics in Catherine Thiéblemont's work include Lymphoma Diagnosis and Treatment (299 papers), Chronic Lymphocytic Leukemia Research (152 papers) and CAR-T cell therapy research (117 papers). Catherine Thiéblemont is often cited by papers focused on Lymphoma Diagnosis and Treatment (299 papers), Chronic Lymphocytic Leukemia Research (152 papers) and CAR-T cell therapy research (117 papers). Catherine Thiéblemont collaborates with scholars based in France, United States and United Kingdom. Catherine Thiéblemont's co-authors include Bertrand Coiffier, Gilles Salles, Pascale Felman, Charles Dumontet, Hervé Tilly, Franck Morschhauser, Françoise Berger, Emanuele Zucca, Evelyne Callet‐Bauchu and Fadhela Bouafia and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Catherine Thiéblemont

393 papers receiving 14.1k citations

Hit Papers

Long-term outcome of pati... 2010 2026 2015 2020 2010 2016 2022 2025 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
    2010 1.1k citations Bertrand Coiffier, Catherine Thiéblemont et al. Blood profile →
  2. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
    2016 328 citations Franck Morschhauser, Gilles Salles et al. profile →
  3. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
    2022 186 citations Sattva S. Neelapu, Michael Dickinson et al. Nature Medicine profile →
  4. T cell malignancies after CAR T cell therapy in the DESCAR-T registry
    2025 23 citations Catherine Thiéblemont, Emmanuel Bachy et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine Thiéblemont France 66 9.9k 7.0k 4.4k 2.4k 2.0k 420 14.3k
Jonathan W. Friedberg United States 61 9.1k 0.9× 6.5k 0.9× 3.8k 0.9× 2.4k 1.0× 1.5k 0.7× 393 12.7k
Nancy L. Bartlett United States 64 11.2k 1.1× 10.0k 1.4× 3.3k 0.8× 2.8k 1.2× 1.7k 0.8× 480 16.8k
Franco Cavalli Switzerland 43 7.7k 0.8× 5.0k 0.7× 2.7k 0.6× 3.2k 1.3× 1.5k 0.7× 190 11.6k
Pier Luigi Zinzani Italy 71 16.3k 1.6× 10.7k 1.5× 5.6k 1.3× 4.0k 1.7× 2.2k 1.1× 924 22.0k
Massimo Federico Italy 45 8.0k 0.8× 5.5k 0.8× 2.1k 0.5× 2.3k 1.0× 919 0.4× 288 12.0k
Joachim Yahalom United States 65 8.6k 0.9× 4.9k 0.7× 3.8k 0.9× 5.6k 2.3× 1.7k 0.8× 272 14.5k
Emanuele Zucca Switzerland 66 16.0k 1.6× 8.3k 1.2× 5.1k 1.2× 5.9k 2.4× 2.4k 1.2× 404 21.0k
Hervé Tilly France 72 17.1k 1.7× 11.5k 1.6× 6.8k 1.6× 4.7k 1.9× 2.5k 1.2× 416 22.5k
Anton Hagenbeek Netherlands 48 11.4k 1.2× 7.7k 1.1× 4.3k 1.0× 3.1k 1.3× 1.7k 0.8× 263 16.4k
Michael Crump Canada 49 5.6k 0.6× 5.3k 0.8× 2.4k 0.5× 1.5k 0.6× 1.6k 0.8× 310 9.8k

Countries citing papers authored by Catherine Thiéblemont

Since Specialization
Citations

This map shows the geographic impact of Catherine Thiéblemont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Thiéblemont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Thiéblemont more than expected).

Fields of papers citing papers by Catherine Thiéblemont

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Thiéblemont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Thiéblemont. The network helps show where Catherine Thiéblemont may publish in the future.

Co-authorship network of co-authors of Catherine Thiéblemont

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Thiéblemont. A scholar is included among the top collaborators of Catherine Thiéblemont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Thiéblemont. Catherine Thiéblemont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chávez, Julio C., Michael Dickinson, Javier Muñoz, et al.. (2025). Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 145(20). 2303–2311. 3 indexed citations
2.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2025). Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 26(2). 200–213. 9 indexed citations
3.
Jiang, Linmiao, Martin Dreyling, Olivier Hermine, et al.. (2024). Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network. British Journal of Haematology. 206(1). 159–166. 1 indexed citations
4.
Morschhauser, Franck, David Belada, Johannes Duell, et al.. (2024). Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma. Blood. 144(Supplement 1). 867–867. 4 indexed citations
5.
Vercellino, Laëtitia, Estelle Blanc, É. de Kerviler, et al.. (2024). Patterns of metabolic response in patients receiving commercial CAR T-cells for relapsing/refractory aggressive B cells lymphoma. British Journal of Radiology. 97(1163). 1755–1764.
6.
Hennequin, Christophe, et al.. (2023). Extranodal nasal-type NK/T lymphoma treated with chemotherapy and radiotherapy: case series from a European tertiary referral center and review of the literature. Strahlentherapie und Onkologie. 200(5). 434–443. 1 indexed citations
7.
Camus, Vincent, Aurélien Belot, Lucie Obéric, et al.. (2022). Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Advances. 6(24). 6169–6179. 8 indexed citations
8.
Neelapu, Sattva S., Michael Dickinson, Javier Muñoz, et al.. (2022). Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nature Medicine. 28(4). 735–742. 186 indexed citations breakdown →
9.
Bernard, Sophie, Hervé Ghesquières, Olivier Casasnovas, et al.. (2021). Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. Blood Advances. 5(15). 2965–2968. 7 indexed citations
10.
Dubois, Sydney, Philippe Ruminy, Élodie Bohers, et al.. (2021). Concomitant occurrence of genetically distinct Hodgkin lymphoma and primary mediastinal lymphoma. SHILAP Revista de lepidopterología. 9(8). e04504–e04504. 2 indexed citations
11.
Calvo-Vidal, M. Nieves, Nahuel Zamponi, Jan Krumsiek, et al.. (2021). Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. Cancer Research. 81(20). 5202–5216. 19 indexed citations
12.
Chettab, Kamel, Marie Potier‐Cartereau, Lars Petter Jordheim, et al.. (2020). Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. Molecular Cancer Therapeutics. 19(11). 2371–2381. 4 indexed citations
13.
Thiéblemont, Catherine, Sylvie Chevret, Vincent Allain, et al.. (2020). Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion. Blood. 136(Supplement 1). 16–17. 16 indexed citations
14.
Reddy, Nishitha & Catherine Thiéblemont. (2017). Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. Annals of Oncology. 28(11). 2680–2690. 12 indexed citations
15.
Cornet, Édouard, Cécile Tomowiak, Aline Schmidt, et al.. (2014). Long‐term follow‐up and second malignancies in 487 patients with hairy cell leukaemia. British Journal of Haematology. 166(3). 390–400. 42 indexed citations
16.
Morschhauser, Franck, Guillaume Cartron, Catherine Thiéblemont, et al.. (2013). Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. Journal of Clinical Oncology. 31(23). 2912–2919. 157 indexed citations
17.
Zucca, Emanuele, Annarita Conconi, Daniele Laszlò, et al.. (2013). Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. Journal of Clinical Oncology. 31(5). 565–572. 148 indexed citations
18.
Casasnovas, Olivier, Michel Meignan, Alina Berriolo-Riedinger, et al.. (2011). SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 118(1). 37–43. 216 indexed citations
19.
Coiffier, Bertrand, Catherine Thiéblemont, Éric Van Den Neste, et al.. (2010). Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 116(12). 2040–2045. 1071 indexed citations breakdown →
20.
Bonnet, Christophe, Georges Fillet, Nicolas Mounier, et al.. (2007). CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology. 25(7). 787–792. 161 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan W. Friedberg Breakdown of academic impact, for papers by Nancy L. Bartlett Breakdown of academic impact, for papers by Franco Cavalli Breakdown of academic impact, for papers by Pier Luigi Zinzani Breakdown of academic impact, for papers by Massimo Federico Breakdown of academic impact, for papers by Joachim Yahalom Breakdown of academic impact, for papers by Emanuele Zucca Breakdown of academic impact, for papers by Hervé Tilly Breakdown of academic impact, for papers by Anton Hagenbeek Breakdown of academic impact, for papers by Michael Crump
Rankless by CCL
2026